eCite Digital Repository

Emerging advances of nanotechnology in drug and vaccine delivery against viral associated respiratory infectious diseases (VARID)

Citation

Seyfoori, A and Barough, MS and Mokarram, P and Ahmadi, M and Mehrbod, P and Sheidary, A and Madrakian, T and Kiumarsi, M and Walsh, T and McAlinden, KD and Ghosh, CC and Sharma, P and Zeki, AA and Ghavami, S and Akbari, M, Emerging advances of nanotechnology in drug and vaccine delivery against viral associated respiratory infectious diseases (VARID), International Journal of Molecular Sciences, 22, (13) pp. 1-31. ISSN 1661-6596 (2021) [Refereed Article]


Preview
PDF
3Mb
  

Copyright Statement

Copyright 2021 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/

DOI: doi:10.3390/ijms22136937

Abstract

Viral-associated respiratory infectious diseases are one of the most prominent subsets of respiratory failures, known as viral respiratory infections (VRI). VRIs are proceeded by an infection caused by viruses infecting the respiratory system. For the past 100 years, viral associated respiratory epidemics have been the most common cause of infectious disease worldwide. Due to several drawbacks of the current anti-viral treatments, such as drug resistance generation and non-targeting of viral proteins, the development of novel nanotherapeutic or nano-vaccine strategies can be considered essential. Due to their specific physical and biological properties, nanoparticles hold promising opportunities for both anti-viral treatments and vaccines against viral infections. Besides the specific physiological properties of the respiratory system, there is a significant demand for utilizing nano-designs in the production of vaccines or antiviral agents for airway-localized administration. SARS-CoV-2, as an immediate example of respiratory viruses, is an enveloped, positive-sense, single-stranded RNA virus belonging to the coronaviridae family. COVID-19 can lead to acute respiratory distress syndrome, similarly to other members of the coronaviridae. Hence, reviewing the current and past emerging nanotechnology-based medications on similar respiratory viral diseases can identify pathways towards generating novel SARS-CoV-2 nanotherapeutics and/or nano-vaccines.

Item Details

Item Type:Refereed Article
Keywords:COVID-19, SARS-CoV-2, nano-vaccine, nanomedicine, respiratory disease, viral infection
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Respiratory diseases
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:McAlinden, KD (Mr Kielan McAlinden)
ID Code:146626
Year Published:2021
Web of Science® Times Cited:5
Deposited By:Health Sciences
Deposited On:2021-09-17
Last Modified:2021-10-28
Downloads:3 View Download Statistics

Repository Staff Only: item control page